MOUNTAIN VIEW, Calif.,
Oct. 8, 2014 /PRNewswire/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its
fiscal quarter ended September 30,
2014 on Wednesday, November 5,
2014, following the close of the U.S. financial
markets. The Company will also host an investor conference
call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company
update and discuss the financial results.
To access the webcast via the Internet, go to www.alexza.com,
under the "Investor Relations" link. Please log onto the
webcast prior to the start of the call to ensure time for any
software downloads that may be required to participate in the
webcast.
LIVE CALL:
888-680-0879 or +1-617-213-4856
(international)
Passcode: 67285958
Interested parties may also pre-register for the call by following
this link.
REPLAY:
888-286-8010 or +1-617-801-6888
(international)
Passcode: 40577066
A replay of the conference call may also be accessed at
www.alexza.com under the "Investor Relations" link. A replay
of the call will be available for 14 days following the event.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato® system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE is Alexza's first commercial product and it has been
approved for sale by the U.S. Food and Drug
Administration, the European Commission, and in Guatemala and Chile. Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical
Industries Ltd., is Alexza's commercial partner for ADASUVE in the
U.S. Ferrer is Alexza's commercial partner for ADASUVE in
Europe, Latin America and the Commonwealth of
Independent States countries. For more information, visit
www.alexza.com.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
The anticipated news release
and conference call will contain forward-looking statements that
involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities
Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of
Alexza and its partners, Teva and Ferrer, to effectively and
profitably commercialize ADASUVE, estimated product revenues and
royalties associated with the sale of ADASUVE, the adequacy
of the Company's capital to support the Company's operations, and
the Company's ability to raise additional funds and the potential
terms of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2013 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
SOURCE Alexza Pharmaceuticals, Inc.